Table 2. Positive prognostic factors and safety of treating BCLM.
| First author (reference) | Positive prognostic factors (multivariate analysis/univariate analysis) | Mortality | Complications | Hospital stay (days)* |
|---|---|---|---|---|
| Abbott (34) | Hormone receptor positive (primary), preoperative SD/DFS interval >2 years | 0% | 21% | 6 |
| Dittmar (35) | R0 resection, no EHM, HER2 expression, age <50 years of age/BCLM <5 cm | 0% | 24% | NS |
| Mariani (36) | EHM (bone), N stage (primary)/hormone receptor positive (primary) | 0% | 18% | NS |
| Kostov (37) | Hormone receptor positive (primary), R0 resection, BCLM <4 cm, response to nonsurgical treatment, negative portal LN | 2% | 36% | NS |
| Polistina (38) | Hormone receptor positive (primary), Number of metastases <3 | 0% | 42% | NS |
| Treska (39)* | Hormone receptor positive (primary), BCLM <3.5 cm, no EHM, age >50 years of age, DFS interval >4 years | NS | NS | NS |
| Bacalbasa (40) | Hormone receptor positive (primary)/BCLM <5 cm, number of metastases, N stage (primary) | NS | NS | NS |
| Weinrich (41) | Low grade (primary)/R0 resection, Number of metastases, T and N stage (primary) | NS | NS | 7 |
| Ruiz (42) | Number of metastases/Hormone receptor positive (primary), DFS interval >2 years | 5% | 32% | 11 |
| Margonis (43) | R0 resection, BCLM <3 cm | 0% | 23% | NS |
| Ruiz (44) | NS | NS | 34% | 10 |
*, median. SD, stable disease; DFS, disease-free survival; R0, microscopic negative margin; EHM, extra hepatic metastases; BCLM, breast cancer liver metastases; LN, lymph nodes; NS, not stated.